Human ELSA kit detection utilizes a discovery platform composed of components from yeast cells to human stem cells. Whitehead Institute scientists have identified a new drug target for Parkinson's disease and confirmed that a compound can repair Parkinson's disease The patient's neurons. Protein misfolding leads to the accumulation of protein toxicity in the cells of the central nervous system, which is characteristic of neurodegenerative diseases such as Parkinson's disease (PD), Huntington's disease, and Alzheimer's disease. For example, the detection of human ELSA kits using α-synuclein (α-Synuclein, α-Syn) accumulated in cells has long been associated with Parkinson ’s disease, making this protein a seemingly appropriate therapeutic intervention target. In the search for compounds that have the potential to alter the behavior or function of a protein (such as alpha-synuclein), drug companies often rely on so-called target-based screening strategies to test large numbers in a rapid and automated manner The effect of the compound on the protein. Although effective, such screening is basically limited to test tubes. Target-based screening found that some seemingly promising compounds may have very different effects when transferred from an in vitro environment to a living environment. Screening nearly 200,000 compounds, Tardiff and colleagues identified a chemical entity that not only reversed alpha-synuclein toxicity in yeast cells, but also partially rescued nematode models and rats Neuron. Treated with the identified compound, some cell pathologies including impaired cell trafficking and increased oxidative stress are significantly reduced. Tardiff found that this compound works by repairing a cellular protein-mediated function. The detection of this protein by the human ELSA kit is essential for cell trafficking and was previously considered "no medicine." But can these findings be applied to human cells? To answer this question, the husband and wife team of Chee-Yeun Chung and Vikram Khurana led a second study in Science magazine that examined neurons generated from induced pluripotent stem cells (iPS cells) from patients with Parkinson's disease. These cells and differentiated neurons are derived from patients with α-synuclein mutations that form invasive Parkinson's disease. To ensure that all pathology in these cultured neurons was attributed only to genetic defects, the researchers also derived control neurons from iPS cells whose mutations have been corrected. "Many people, including ourselves, are skeptical that we can reprogram patient cells to discover an important pathology of a neurodegenerative disease. But the point is, we also verified these pathologies in the brain after death, So we are confident that these are related to Parkinson ’s disease. " "The human ELSA kit test discovered the use of yeast genetics to identify a compound and its mechanism for the underlying pathology of a disease, confirming the ability of this system we built. We continue to use this ability very Important, because as we reduce the death rate of cancer and heart disease, the burden of these terrible neurodegenerative diseases will increase, which is inevitable. " Rechargeable Nose Hair Trimmer Rechargeable Nose Hair Trimmer,Nose Hair Trimmers For Men,Custom Nose Hair Trimmer,Adult Nose Hair Trimmer ZHEJIANG SHENGFA ELECTRIC APPLIAMNCES CO.,LTD , https://www.sfelectricappliances.com